Blog Index
The journal that this archive was targeting has been deleted. Please update your configuration.

Our Pipeline and Portfolio Companies

TAO Life Sciences has acquired interests in several technologies with strong commercial potential, with their roots in universities and private companies. Our pipeline provides a blend of near- and mid-term products, each of which will generate returns within 18 months of inception.

Each of the products we are currently developing are anticipated to be eligible for FDA 510(k) regulatory approval, a relatively rapid route generally taking between three and six months.

We have advanced three of our products to working prototypes and are evaluating their performance. We are developing two additional products, each of which is in the early stage of engineering design and clinical trial planning.

For selected opportunities, we advance the product development further and establish a Portfolio Company, a separate corporate entity, infused with capital, management and technology with an eye towards further investment and specialized management.